Mithra Finalizes Estelle® Contract with Brazilian Women’s Health Leader Libbs

  • Mithra is eligible for a EUR 20 million upfront milestone payment, with EUR 14 million to be received in 2017
  • 20-year contract grants Libbs an exclusive commercial license as well as manufacturing rights for Estelle® in Brazil, in addition to a cost-effective alternative supply option for key APIs (Active Pharmaceutical Ingredients)
  • Contract forms part of Mithra’s strategy to realize full potential of pipeline programs through global partnerships with leaders in Women’s Health

Liège, Belgium, 11 December 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, is pleased to announce finalization and signature of the contract with Libbs, the Women’s Health leader in Brazil, for an exclusive license to Estelle® in Brazil. This follows the binding Heads of Terms announced in September 2017. Estelle® is Mithra’s novel oral contraceptive product candidate composed of 15 mg Estetrol (E4) and 3 mg drospirenone (DRSP). Estelle® is currently in Phase III trials in the US and Canada as well as in Europe and Russia, with top line results expected in Q3 2018 and Q1 2019, respectively.